Search results for "Retinoid"

showing 10 items of 79 documents

Glucocorticoids as modulators of expression and activity of Antithrombin (At): potential clinical relevance.

2014

Abstract Introduction An inverse relationship has been reported between decreased postoperative Antithrombin (AT) plasmatic levels and the incidence of complications. We hypothesized that Nuclear Hormone Receptors could modulate the expression of SERPINC1 , encoding AT, through a Hormone Regulatory Element present in its promoter, and thus hormone analogs could be a pharmacological complement in surgical procedures to activate endogenous AT synthesis. Materials and Methods The expression of SERPINC1 was analyzed in HepG2 cells by quantitative RT-PCR and Western Blot. Two studies were conducted with (a) patients submitted to cardiac surgery with cardiopulmonary bypass receiving (n =17) or no…

Malemedicine.medical_specialtyMolecular Sequence DataReceptors Cytoplasmic and NuclearRetinoid X receptorLigandsAntithrombinsCohort StudiesRetinoidsInternal medicinemedicineHumansGlucocorticoidsDexamethasoneAgedCardiopulmonary BypassBase Sequencebusiness.industryAntithrombinRNA-Binding ProteinsHematologyHep G2 CellsIsoxazolesMiddle AgedEndocrinologyRetinoid X ReceptorsTreatment OutcomeMethylprednisoloneNuclear receptorHemostasisFemaleCortisonebusinessHormonemedicine.drugThrombosis research
researchProduct

Low dose of isotretinoin: A comprehensive review

2020

Isotretinoin is a first-generation retinoid initially approved for the treatment of severe cases of acne vulgaris (nodulocystic acne). Because of its broad anti-inflammatory and immunomodulatory properties, it has been used beyond its initial approval in a myriad of other indications. Adverse effects of isotretinoin vary from xerosis to teratogenicity. Herein, we reviewed the literature, through date-unlimited PubMed search, from inception till December 2019, using the following search terms: "low-dose isotretinoin" and "dermatology," "isotretinoin and safety," "isotretinoin, off-label uses," "isotretinoin and male fertility," "isotretinoin, iPLEDGE system," aiming to deliver a therapeutic …

Malemedicine.medical_specialtyNodulocystic acneDermatologyRetinoids030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineAcne VulgarismedicineHumansIsotretinoinskin and connective tissue diseasesAdverse effectIsotretinoinAcnebusiness.industryLow doseGeneral Medicinemedicine.diseaseDermatologyClinical PracticeSafety profileSearch terms030220 oncology & carcinogenesisDermatologic Agentsbusinessmedicine.drugDermatologic Therapy
researchProduct

Up‐regulation of the α‐secretase ADAM10 by retinoic acid receptors and acitretin

2009

Late-onset Alzheimer's disease is often connected with nutritional misbalance, such as enhanced cholesterol intake, deficiency in polyunsaturated fatty acids, or hypovitaminosis. The alpha-secretase ADAM10 has been found to be regulated by retinoic acid, the bioreactive metabolite of vitamin A. Here we show that retinoids induce gene expression of ADAM10 and alpha-secretase activity by nonpermissive retinoid acid receptor/retinoid X receptor (RAR/RXR) heterodimers, whereby alpha- and beta-isotypes of RAR play a major role. However, ligands of other RXR binding partners, such as the vitamin D receptor, do not stimulate alpha-secretase activity. On the basis of these findings, we examined the…

Malemedicine.medical_specialtyReceptors Retinoic AcidReceptors Cytoplasmic and NuclearMice TransgenicTretinoinRetinoic acid receptor betaRetinoid X receptorBiologyBiochemistryCell LineAcitretinADAM10 ProteinAmyloid beta-Protein PrecursorMiceKeratolytic AgentsAlzheimer DiseaseInternal medicineGeneticsmedicineAnimalsHumansPromoter Regions GeneticMolecular BiologyLiver X ReceptorsReceptors Thyroid HormoneMolecular StructureRetinoid X receptor alphaMembrane ProteinsOrphan Nuclear ReceptorsRetinoid X receptor gammaAcitretinUp-RegulationDNA-Binding ProteinsPPAR gammaADAM ProteinsRetinoic acid receptorRetinoid X ReceptorsEndocrinologyGene Expression RegulationRetinoic acid receptor alphaReceptors CalcitriolAmyloid Precursor Protein SecretasesRetinoid X receptor betaBiotechnologymedicine.drugThe FASEB Journal
researchProduct

Engineering of Nanofibrous Amorphous and Crystalline Solid Dispersions for Oral Drug Delivery

2018

Poor aqueous solubility (<0.1 mg/mL) affects a significant number of drugs currently on the market or under development. Several formulation strategies including salt formation, particle size reduction, and solid dispersion approaches have been employed with varied success. In this review, we focus primarily on the emerging trends in the generation of amorphous and micro/nano-crystalline solid dispersions using electrospinning to improve the dissolution rate and in turn the bioavailability of poorly water-soluble drugs. Electrospinning is a simple but versatile process that utilizes electrostatic forces to generate polymeric fibers and has been used for over 100 years to generate synthet…

Materials scienceamorphousoral drug deliveryPharmaceutical Sciencelcsh:RS1-44102 engineering and technologyReview030226 pharmacology & pharmacylcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineamorphoucrystallineaqueous solubility enhancementDissolutionelectrospinningsolid dispersion021001 nanoscience & nanotechnologyElectrospinningAmorphous solidSynthetic fiberChemical engineeringPARTICLE SIZE REDUCTION0210 nano-technologyDispersion (chemistry)Oral retinoidSalt formation
researchProduct

Dual-capillary electroencapsulation of mesoporous silicon drug carrier particles for controlled oral drug delivery

2012

Abstract The feasibility of electroencapsulation of mesoporous silicon (PSi) micro- and nanoparticles as a method to seal the PSi particles in mechanically processable solid units, and to facilitate time and site specific drug release from the pores of PSi particles, is of interest in the present work. Suitable microcapsules and micromatrix particles were produced in a single-step process using a setup with two electrospraying nozzles kept at high electric potentials of opposite polarities. The structures of the produced particles were analyzed by microscope and X-ray micro- and nanotomography imaging, and optimization of the electroencapsulation process production efficiency is discussed.

MicroscopeMaterials scienceSiliconta114Capillary actionchemistry.chemical_elementNanoparticleNanotechnologyCondensed Matter PhysicsSurfaces Coatings and FilmsElectronic Optical and Magnetic Materialslaw.inventionchemistrylawDrug deliveryElectrical and Electronic EngineeringDrug carrierMesoporous materialOral retinoidBiotechnologyJournal of Electrostatics
researchProduct

Six years of progress in the oral biopharmaceutics area - A summary from the IMI OrBiTo project.

2020

OrBiTo was a precompetitive collaboration focused on the development of the next generation of Oral Biopharmaceutics Tools. The consortium included world leading scientists from nine universities, one regulatory agency, one non-profit research organisation, three small/medium sized specialist technology companies together with thirteen pharmaceutical companies. The goal of the OrBiTo project was to deliver a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This goal was achieved through novel prospective investigations to define new methodologies or refinement of existing tools. Extensive validation has been performed of novel and existing biop…

PBPKEngineeringBest practicePharmaceutical ScienceAdministration Oral02 engineering and technology030226 pharmacology & pharmacyPermeabilityBiopharmaceutics03 medical and health sciences0302 clinical medicineDrug Delivery SystemsGastrointestinal drug absorptionDrug DevelopmentAnimalsHumansProspective StudiesIVIVCDrug absorptionbusiness.industryBiopharmaceuticsIndustrial researchGeneral Medicine021001 nanoscience & nanotechnologyGastrointestinal TractEngineering managementDrug developmentIntestinal AbsorptionPharmaceutical PreparationsNew product developmentRegulatory agency0210 nano-technologybusinessDissolutionOral retinoidBiotechnologyEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

The analysis of modified peroxisome proliferator responsive elements of the peroxisomal bifunctional enzyme in transfected HepG2 cells reveals two re…

1995

AbstractPeroxisome proliferators (PPs) are non-genotoxic carcinogens in rodents. They can induce the expression of numerous genes via the heterodimerization of two members of the steroid hormone receptor superfamily, called the peroxisome proliferator-activated receptor (PPAR) and the 9-cis retinoic acid receptor (RXR). Many of the PP responsive genes possess a peroxisome proliferator response element (PPRE) formed by two TGACCT-related motifs. The bifunctional enzyme (HD) PPRE contains 3 such motifs, creating DR1 and DR2 sequences. PPAR and RXR regulate transcription via the DR1 element while DR2 modulates the expression of the gene via auxiliary factors in HepG2 cells.

Peroxisome proliferator-activated receptor gammaReceptors Retinoic AcidSteroid hormone receptorMolecular Sequence DataResponse elementBiophysicsReceptors Cytoplasmic and NuclearPeroxisome proliferator-activated receptorchemical and pharmacologic phenomenaIn Vitro TechniquesRegulatory Sequences Nucleic AcidRetinoid X receptorBiologyPeroxisomal Bifunctional EnzymeTransfectionMicrobodiesBiochemistryGene Expression Regulation EnzymologicTranscriptional activationPeroxisomal Bifunctional EnzymeMultienzyme ComplexesStructural BiologyPeroxisome proliferator response element9-cis Retinoic acid receptor alphaTumor Cells CulturedGeneticsHumansRNA MessengerIsomerasesEnoyl-CoA HydrataseMolecular Biologychemistry.chemical_classificationBinding SitesBase Sequence3-Hydroxyacyl CoA DehydrogenasesPeroxisome proliferator-activated receptorCell BiologyDNA-Binding ProteinsRetinoic acid receptorRetinoid X ReceptorsLiverOligodeoxyribonucleotidesBiochemistrychemistryRat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenaseEnzyme InductionPeroxisome proliferator-activated receptor alphaTranscription FactorsFEBS Letters
researchProduct

Functional characterization of a peroxisome proliferator response-element located in the intron 3 of rat peroxisomal thiolase B gene.

2003

Expression of the rat peroxisomal 3-ketoacyl-CoA thiolase gene B is induced by peroxisome proliferators. Although a sequence element like a peroxisome proliferator-activated receptor (PPAR)-binding site is located in the promoter region of this gene, we previously found that this element is competent for the activation by hepatocyte nuclear factor-4, but not functional with PPARalpha. We describe here a new peroxisome proliferator-response element located in the intron 3 (+1422/+1434) that binds in vitro the PPARalpha/retinoid X receptor alpha heterodimer and confers the induction by PPARalpha in transfection assays. We propose a model of regulation of the rat thiolase B gene involving thos…

Peroxisome proliferator-activated receptor gammaResponse elementBiophysicsPeroxisome proliferator-activated receptorReceptors Cytoplasmic and NuclearRetinoid X receptorBiochemistryGene Expression Regulation EnzymologicStructure-Activity RelationshipPeroxisomesAnimalsAcetyl-CoA C-AcetyltransferaseMolecular BiologyCells Culturedchemistry.chemical_classificationThiolaseChemistryCell BiologyPhosphoproteinsMolecular biologyIntronsRatsDNA-Binding ProteinsBiochemistryHepatocyte Nuclear Factor 4LiverPeroxisome proliferator-activated receptor deltaPeroxisome ProliferatorsPeroxisome proliferator-activated receptor alphaPPARGC1BTranscription FactorsBiochemical and biophysical research communications
researchProduct

Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE−/−mice and angiogenesis

2015

Background and Purpose Abdominal aortic aneurysm (AAA) is a degenerative vascular disease associated with angiogenesis. Bexarotene is a retinoid X receptor (RXR) ligand with anti-angiogenic activity. Statins also exert anti-angiogenic activity and activate PPARs. Because RXR ligands form permissive heterodimers with PPARs and a single anti-angiogenic drug may not be sufficient to combat the wide array of angiogenic factors produced during AAA, we evaluated the effect of combined low doses of bexarotene and rosuvastatin in a mouse model of AAA.

PharmacologyBexaroteneAngiogenesisPharmacologyRetinoid X receptorBiologymedicine.diseaseenvironment and public healthAngiotensin IINeovascularizationAortic aneurysmRosuvastatin Calciumcardiovascular systemmedicinelipids (amino acids peptides and proteins)Rosuvastatincardiovascular diseasesmedicine.symptommedicine.drugBritish Journal of Pharmacology
researchProduct

Formulation predictive dissolution (fPD) testing to advance oral drug product development: an introduction to the US FDA funded ‘21st Century BA/BE’ …

2018

Over the past decade, formulation predictive dissolution (fPD) testing has gained increasing attention. Another mindset is pushed forward where scientists in our field are more confident to explore the in vivo behavior of an oral drug product by performing predictive in vitro dissolution studies. Similarly, there is an increasing interest in the application of modern computational fluid dynamics (CFD) frameworks and high-performance computing platforms to study the local processes underlying absorption within the gastrointestinal (GI) tract. In that way, CFD and computing platforms both can inform future PBPK-based in silico frameworks and determine the GI-motility-driven hydrodynamic impac…

Physiologically based pharmacokinetic modellingBioavailabilityComputer scienceManometryDrug CompoundingAdministration OralPharmaceutical Science02 engineering and technologyBioequivalenceComputational fluid dynamics030226 pharmacology & pharmacyArticleDOSAGE FORMSINDUCED VARIABILITY03 medical and health sciences0302 clinical medicineBIOPHARMACEUTICS CLASSIFICATION-SYSTEMABSORPTIONHumansDissolution testingOral absorptionPharmacology & PharmacyDissolutionIN-VIVO DISSOLUTIONIn vivo dissolutionBioequivalenceScience & TechnologyWORKSHOP REPORTUnited States Food and Drug Administrationbusiness.industryGASTROINTESTINAL SIMULATOR GISVITRO DISSOLUTION021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemUnited StatesMODELDrug LiberationNew product developmentPredictive powerDIFFUSION-CONTROLLED DISSOLUTIONBiochemical engineering0210 nano-technologybusinessLife Sciences & BiomedicineOral retinoidMRI
researchProduct